Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3182055 | 1.00 | RAB9A (0.51) | RAB9AHSD11B1NPC1CASP3SENP8 | |
| SCHEMBL3175124 | 1.00 | RAB9A (0.51) | RAB9AHSD11B1NPC1CASP3SENP8 | |
| SCHEMBL3664032 | 0.89 | LMNA (0.42) | RAB9AHSD11B1NPC1MEN1KMT2A | |
| SCHEMBL3173484 | 0.89 | LMNA (0.42) | RAB9AHSD11B1NPC1MEN1KMT2A | |
| SCHEMBL3171841 | 0.89 | LMNA (0.42) | RAB9AHSD11B1NPC1MEN1KMT2A | |
| SCHEMBL3546870 | 0.82 | SCD5 (0.41) | MEN1KMT2ASCD5ALDH1A1RXFP1 | |
| SCHEMBL3179223 | 0.82 | HSD11B1 (0.47) | RAB9AHSD11B1NPC1CASP3SENP8 | |
| SCHEMBL3973223 | 0.82 | SCD5 (0.41) | MEN1KMT2ASCD5ALDH1A1RXFP1 | |
| SCHEMBL3181418 | 0.82 | PDE2A (0.39) | RAB9AHSD11B1NPC1KMT2AALDH1A1 | |
| SCHEMBL3666251 | 0.82 | PDE2A (0.39) | RAB9AHSD11B1NPC1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231650-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Biovitrum AB (publ) (SE) | 2010-09-29 | — | — | EP | claimed |
| US-20100022590-A1 | Novel compounds | BIOVITRUM AB (PUBL.) (SE) | 2010-01-28 | — | — | US | claimed |
| WO-2009090239-A1 | ISOXAZOLE DERIVATIVES AS MODULATORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (PUBL) (SE) | 2009-07-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022590-A1 | Novel compounds | HSD11B1, CYP11B1, HSD11B2 | RAB9A 2623/4885HSD11B1 1/4885NPC1 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.